Moffitt Cancer Center ACD & Division Chief, Basic Science. Cancer Biologist. Discovery Science.
Tampa, FL
Joined February 2020
- Tweets554
- Following1.1K
- Followers745
- Likes2.9K
Elsa Renee Flores retweeted
From the Moffitt booth at #AACR26, insights from Elsa Flores, PhD (@LabElsaFlores), and Brian Ruffell, PhD (@Ruffell_Lab), on how tumor cells may evade immune recognition through surface molecules, particularly in genomically unstable breast cancers. #MoffittAACR26 @AACR
Elsa Renee Flores retweeted
From the floor at #AACR26, a conversation between Elsa Flores, PhD (@LabElsaFlores), and Chang Jiang, PhD (@ChangJiangLab), on how cancer metabolism research, including dendritic cell metabolism, may enhance immune responses and improve therapies like CAR T-cell treatment. #MoffittAACR26 @AACR
Elsa Renee Flores retweeted
While at #AACR26, Elsa Flores, PhD (@LabElsaFlores), and Florian Karreth, PhD (@KarrethLab), took some time to discuss how non-genetic events drive melanoma progression and how new rapid preclinical models are helping accelerate cancer research. #MoffittAACR26 @AACR
Elsa Renee Flores retweeted
Earlier at #AACR26, Elsa Flores, PhD (@LabElsaFlores), and Andrii Monastyrskyi, PhD, took a moment to discuss how emerging drug discovery approaches, including protein degradation and AI-driven design, are advancing new cancer therapies. #MoffittAACR26 @AACR
Had a memorable and exciting day celebrating Moffitt Cancer Center and the Moffitt Discovery and Innovation Center! Thank you to @TsoiKobus and @WhitingTurner !! @MoffittNews @Timadams2023 @PatrickHwuMD @HLeeMoffitt1
Elsa Renee Flores retweeted
Thrilled to share our deconstruction of a p53 therapeutic response in #LUAD- a step toward drugging #undruggable #p53! Thanks to our amazing team! @wmx162005 @alyssamkaiser @kbieging @LabElsaFlores @MikeOzawa @MLadanyi @arati_rajeevan @rajnitin @simone_alma
Now online: p53 Drives Lung Cancer Regression through a TSC2/TFEB-Dependent Senescence Program doi.org/10.1158/2159-8290.CD…
This morning, I was thrilled to show off the progress on the Moffitt Discovery and Innovation Center at SPEROS. I can’t wait to make new discoveries with my colleagues using trans disciplinary approaches. Big thank you to @PatrickHwuMD @HLeeMoffitt1 @john Cleveland for the opportunity to lead this effort! @MoffittNews
Elsa Renee Flores retweeted
James V. DeGregori, Emilia Lim, William Hill, and Kenneth Y. Tsai discussed "Early Events and Clonal Origins" in a plenary session at the AACR Special Conference on Cancer Evolution.
#AACRevol25 @LimEmilia @DrWilliamHill @KYTsaiLab
A pioneer and an inspiration!
In Conversation with Robert S. Langer | ACS Nano Medicine pubs.acs.org/doi/10.1021/acs…
Great day at Miles for Moffitt with my team Research Rangers and my daughter, Athena! @MoffittNews @PatrickHwuMD @HLeeMoffitt1
Elsa Renee Flores retweeted
At #SITC25, Kenneth Tsai, MD (@KYTsaiLab), presents Phase II results showing a 57.7% pCR with neoadjuvant lenvatinib plus pembrolizumab in stage II–IV Merkel cell carcinoma. Responders show interferon and ANGPTL1 signaling; nonresponders show neural and E2F/MYC pathways with higher baseline Tregs. #MoffittSITC25
Highlights from the Jaeger Lab at SITC!
Tomorrow at #SITC25, Christopher Polera will share research on how RAS inhibition reshapes the tumor immunopeptidome to reveal new immunogenic targets and inform combination immunotherapy strategies.
#MoffittSITC25 @sitcancer
Great Moffitt basic science at SITC!
At #SITC25, Alex Jaeger, PhD joins Greg Sawyer, PhD (@ProfGregSawyer) to discuss the work his lab is presenting, including the immunopeptidome, MHC-I and MHC-II. #MoffittSITC25
Elsa Renee Flores retweeted
Live from #SITC25: Kenneth Tsai, MD (@KYTsaiLab) presents data showing that Pembrolizumab plus Levatinib demonstrated encouraging efficacy as neoadjuvant therapy for resectable clinical stage II-IV Merkel cell carcinoma.
Elsa Renee Flores retweeted
Tomorrow at #SITC25: Kenneth Tsai, MD, PhD (@KYTsaiLab) presents a late-breaking abstract on the molecular and immunologic correlates of response in the phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.
#MoffittSITC25 @sitcancer
Excited to share our new paper in @PNAS!
We developed biodegradable biomaterials that organize immune cells into tertiary lymphoid–like structures, potentially improving outcomes for patients less responsive to immunotherapies.
@DrJamesMule @MoffittNews
doi.org/10.1073/pnas.2409560…
Elsa Renee Flores retweeted
#ScienceSaturday
❓ Some people with multiple myeloma respond well to CAR T-cell therapy, but others relapse when the cancer finds ways to hide. Why does that happen, and how can we fix it?
➡️ Dr. Fabiana Perna and colleagues at Moffitt Cancer Center, found that one reason is that some myeloma cells don’t have enough of a target protein called BCMA, which CAR T cells need to find and attack the cancer.
➡️ To solve this, the team designed a new kind of CAR T cell that looks for a different target called SEMA4A. This protein is common on myeloma cells—even in patients whose cancer came back after BCMA-CAR T therapy.
➡️ In lab and mouse studies, these SEMA4A-CAR T cells destroyed myeloma cells that regular BCMA-CAR T cells couldn’t reach, showing promise for treating relapsed patients in the future.
🌟 This research could lead to next-generation cell therapies that keep multiple myeloma from coming back and help more patients stay cancer-free longer. @fabianaperna @MoffittNews
🔗 Read more in Cancer Cell: doi.org/10.1016/j.ccell.2025…
Congratulations @LabKissil ! Exciting new model of lung cancer! @MoffittNews @PatrickHwuMD @KYTsaiLab
